Your browser doesn't support javascript.
loading
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
El-Galaly, Tarec Christoffer; Villa, Diego; Michaelsen, Thomas Yssing; Hutchings, Martin; Mikhaeel, Nabegh George; Savage, Kerry J; Sehn, Laurie H; Barrington, Sally; Hansen, Jakob W; Smith, Daniel; Rady, Kirsty; Mylam, Karen J; Larsen, Thomas S; Holmberg, Staffan; Juul, Maja B; Cordua, Sabrina; Clausen, Michael R; Jensen, Kristina B; Johnsen, Hans E; Seymour, John F; Connors, Joseph M; de Nully Brown, Peter; Bøgsted, Martin; Cheah, Chan Y.
Afiliação
  • El-Galaly TC; Department of Hematology, Aalborg University Hospital, Mølleparkvej 4, DK-9100 Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Sdr. Skovvej 15, 9100 Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Sdr. Skovvej 15, DK-9000 Aalborg, Denmark. Elect
  • Villa D; Division of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, 150-686 W. Broadway, Vancouver, BC, Canada.
  • Michaelsen TY; Department of Hematology, Aalborg University Hospital, Mølleparkvej 4, DK-9100 Aalborg, Denmark.
  • Hutchings M; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9 DK-2100 Copenhagen, Denmark.
  • Mikhaeel NG; Department of Clinical Oncology, Guy's and St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.
  • Savage KJ; Division of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, 150-686 W. Broadway, Vancouver, BC, Canada.
  • Sehn LH; Division of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, 150-686 W. Broadway, Vancouver, BC, Canada.
  • Barrington S; PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.
  • Hansen JW; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9 DK-2100 Copenhagen, Denmark.
  • Smith D; Department of Clinical Oncology, Guy's and St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.
  • Rady K; Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, 305 Grattan Street, Melbourne VIC 3000, Australia.
  • Mylam KJ; Department of Hematology, Odense University Hospital, Søndre Boulevard 29, DK-5000 Odense, Denmark.
  • Larsen TS; Department of Hematology, Odense University Hospital, Søndre Boulevard 29, DK-5000 Odense, Denmark.
  • Holmberg S; Department of Hematology, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
  • Juul MB; Department of Hematology, Vejle Hospital, Kabbeltoft 25, DK-7100 Vejle, Denmark.
  • Cordua S; Department of Hematology, Roskilde Hospital, Zealand University Hospital, Sygehusvej 10, DK-4000 Roskilde, Denmark.
  • Clausen MR; Department of Hematology, Aarhus University Hospital, Tage-Hansens Gade 2, DK-8000 Aarhus, Denmark.
  • Jensen KB; Department of Hematology, Holstebro Hospital, Lægårdvej, DK-7500 Holstebro, Denmark.
  • Johnsen HE; Department of Hematology, Aalborg University Hospital, Mølleparkvej 4, DK-9100 Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Sdr. Skovvej 15, 9100 Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Sdr. Skovvej 15, DK-9000 Aalborg, Denmark.
  • Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, 305 Grattan Street, Melbourne VIC 3000, Australia.
  • Connors JM; Division of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, 150-686 W. Broadway, Vancouver, BC, Canada.
  • de Nully Brown P; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9 DK-2100 Copenhagen, Denmark.
  • Bøgsted M; Department of Hematology, Aalborg University Hospital, Mølleparkvej 4, DK-9100 Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Sdr. Skovvej 15, 9100 Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Sdr. Skovvej 15, DK-9000 Aalborg, Denmark.
  • Cheah CY; Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, 305 Grattan Street, Melbourne VIC 3000, Australia; Department of Hematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Hospital Ave, Nedlands WA 6009, Australia; University of Western Australi
Eur J Cancer ; 75: 195-203, 2017 04.
Article em En | MEDLINE | ID: mdl-28237865
ABSTRACT

PURPOSE:

Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients at greatest risk, but the optimal model is unknown.

METHODS:

We retrospectively analysed patients with diffuse large B-cell lymphoma diagnosed between 2001 and 2013, staged with PET/CT and treated with R-CHOP(-like) regimens. Baseline clinicopathologic characteristics, treatments, and outcome data were collected from clinical databases and medical files. We evaluated the association between candidate prognostic factors and modelled different risk models for predicting SCNS.

RESULTS:

Of 1532 patients, 62 (4%) subsequently developed SCNS. By multivariate analysis, disease stage III/IV, elevated serum LDH, kidney/adrenal and uterine/testicular involvement were independently associated with SCNS. There was a strong correlation between absolute number of extranodal sites and risk of SCNS; the 144 patients (9%) with >2 extranodal sites had a 3-year cumulative incidence of SCNS of 15.2% (95% confidence interval [CI] 9.2-21.2%) compared with 2.6% (95% CI 1.7-3.5) among those with ≤2 sites (P < 0.001). The 3-year cumulative risks of SCNS for CNS-IPI defined risk groups were 11.2%, 3.1% and 0.4% for high-, intermediate- and low-risk patients, respectively. All risk models analysed had high negative predictive values, but only modest positive predictive values.

CONCLUSIONS:

Patients with >2 extranodal sites or high-risk disease according to the CNS-IPI should be considered for baseline CNS staging. Clinical risk prediction models suffer from limited positive predictive ability, highlighting the need for more sensitive biomarkers to identify patients at highest risk of this devastating complication.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B / Neoplasias do Sistema Nervoso Central / Imunoterapia / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B / Neoplasias do Sistema Nervoso Central / Imunoterapia / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article